Sun, December 21, 2008
Fri, December 19, 2008
Thu, December 18, 2008
Wed, December 17, 2008
Tue, December 16, 2008
Mon, December 15, 2008
Sun, December 14, 2008
Fri, December 12, 2008
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
Mon, December 8, 2008
Sun, December 7, 2008
Sat, December 6, 2008
Fri, December 5, 2008
Thu, December 4, 2008
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ]: Market Wire
Protherics PLC: Offer Update
Tue, December 2, 2008
Mon, December 1, 2008
Sun, November 30, 2008
Fri, November 28, 2008
Thu, November 27, 2008
Wed, November 26, 2008

Sucampo Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2008/ .. e-rbc-capital-markets-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

BETHESDA, MD--([ BUSINESS WIRE ])--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that management will participate in a panel discussion titled Going With Your Gut: New Treatments for GI Disorders at the RBC Capital Markets Healthcare Conference in New York on Wednesday, December 10, 2008 at 1:30pm.

The panel discussion will be webcast and may be accessed at the "For Investors" section of the Company's website, [ www.sucampo.com ]. Investors interested in listening to the live audio webcast should log on before the conference call begins in order to download any software required. The archive of the panel discussion will remain available for several days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and Advisor, International Business Development.

Sucampo Pharmaceuticals is marketing AMITIZA® (lubiprostone) 24 mcg in the U.S. for Chronic Idiopathic Constipation in adults and AMITIZA 8 mcg in the U.S. to treat Irritable Bowel Syndrome with Constipation in adult women. Sucampo is also developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK, with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit [ www.sucampo.com ].

AMITIZA® is a registered trademark of Sucampo Pharmaceuticals, Inc.


Similar Health and Fitness Publications